Fri, April 12, 2013
Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013
Tue, April 2, 2013
Mon, April 1, 2013
Fri, March 29, 2013
Thu, March 28, 2013
Wed, March 27, 2013
Tue, March 26, 2013
Mon, March 25, 2013
[ Mon, Mar 25th 2013 ] - Market Wire
Health Canada Decision Appealed
Sun, March 24, 2013
Fri, March 22, 2013
Thu, March 21, 2013
Wed, March 20, 2013
[ Wed, Mar 20th 2013 ] - Market Wire
00am ET
Tue, March 19, 2013
Mon, March 18, 2013
Sun, March 17, 2013
Fri, March 15, 2013

Threshold Pharmaceuticals Announces Presentation and Webcast at the 20th Annual Future Leaders in the Biotech Industry Conferen


//health-fitness.news-articles.net/content/2013/ .. re-leaders-in-the-biotech-industry-conferen.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


April 01, 2013 07:00 ET

Threshold Pharmaceuticals Announces Presentation and Webcast at the 20th Annual Future Leaders in the Biotech Industry Conference

SOUTH SAN FRANCISCO, CA--(Marketwire - Apr 1, 2013) - Threshold Pharmaceuticals, Inc. (NASDAQ: [ THLD ]) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 20th Annual Future Leaders in the Biotechnology Industry Conference at 8:30 a.m. ET on Friday, April 5, 2013.

A live webcast of the presentation will be available under Webcasts in the Investors section of [ www.thresholdpharm.com ]. A replay of the presentation will be archived on the site for 30 days.

About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors as well as the bone marrows of some patients with hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ([ www.thresholdpharm.com ]).

Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of its product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission on March 7, 2013 and is available from the SEC's website ([ www.sec.gov ]) and on our website ([ www.thresholdpharm.com ]) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.



Publication Contributing Sources